Please use this identifier to cite or link to this item:
|Title:||FATE: the new partnership to Fight Against TB in Central and Eastern Europe||Authors:||Jagielski T.
|Keywords:||bacterial strain;Central European;communicable disease control;drug resistant tuberculosis;Eastern Europe;extensively drug resistant tuberculosis;genotype;human;Letter;multidrug resistant tuberculosis;Mycobacterium tuberculosis;next generation sequencing;nonhuman;organizational structure;priority journal;tuberculosis control;intersectoral collaboration;tuberculosis||Issue Date:||Apr-2017||Publisher:||Elsevier||Journal:||Lancet Infectious Diseases||Abstract:||With its association with HIV and the emergence of drug-resistance, tuberculosis remains the most deadly of all infectious diseases affecting human beings.1 Today, multidrug-resistant and extensively drug-resistant tuberculosis leave patients and physicians with very few treatment options.2 Central and eastern Europe is a hotspot for drug-resistant tuberculosis and most countries in the region face similar threats (figure, appendix) and opportunities, including the introduction of molecular tests for rapid diagnosis of drug-resistant tuberculosis. Yet, regional collaboration and a single recognisable organisation that could act as an interface with other relevant parties, such as the WHO, European Centre for Disease Prevention and Control, non-governmental organisations (NGOs), funding agencies, and scientific consortia, are still lacking. To improve this situation, most relevant tuberculosis authorities in the region, including the national reference laboratories, have set up the Partnership to Fight Against TB in Central and Eastern Europe (FATE).||URI:||https://cris.pasteurorg.ru/handle/123456789/85||ISSN:||1473-3099||DOI:||10.1016/S1473-3099(17)30120-2|
|Appears in Collections:||Cтатьи в журналах/Journal articles|
Show full item record
checked on Dec 7, 2018
checked on Dec 11, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.